A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 25, 2016

Primary Completion Date

December 15, 2017

Study Completion Date

September 6, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Durvalumab

single use vials administered via intravenous infusion

DRUG

Lenalidomide

capsules for oral administration

DRUG

Dexamethasone

tablets for oral administration

Trial Locations (54)

168

Local Institution - 404, Rome

2100

Local Institution - 901, Copenhagen

Rigshospitalet University Hospital, Copenhagen

5000

Local Institution - 903, Odense

Odense Universitetshospital, Odense

7100

Local Institution - 902, Vejle

Vejle Hospital, Vejle

10065

Weill Medical College of Cornell University, New York

10126

Azienda Ospedaliera San Giovanni Battista - Ospedale Molinette, Torino

Local Institution - 406, Torino

27100

I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia

Local Institution - 402, Pavia

28041

Hospital 12 de Octobre, Madrid

Local Institution - 505, Madrid

28203

Carolinas Healthcare System, Charleston

30322

Winship Cancer Institute of Emory University, Atlanta

31008

Clinica Universitaria de Navarra, Pamplona

Local Institution - 501, Pamplona

37007

Hospital Universitario de Salamanca, Salamanca

Local Institution - 503, Salamanca

40138

Local Institution - 405, Bologna

Policlinico S. Orsola, Bologna

42100

Local Institution - 403, Reggio Emilia

Servizio di Ematologia, A.O. - Arcispedale S.Maria Nuova, Reggio Emilia

45122

Universitatsklinikum Essen, Essen

46017

Hospital Doctor Peset, Valencia

Local Institution - 506, Valencia

46026

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

Local Institution - 504, Valencia

56068

Local Institution - 304, Koblenz

Praxis fuer Haematologie und Onkologie Koblenz, Koblenz

72076

Local Institution - 302, Tübingen

University of Tubingen, Tübingen

98104

Swedish Medical Center, Seattle

35294-000

University of Alabama Birmingham, Birmingham

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

T2N 4N2

Local Institution - 206, Calgary

Tom Baker Cancer Center, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

Local Institution - 203, Edmonton

V5Z 4E6

British Columbia Cancer Agency, Vancouver

B3H 2Y9

Local Institution - 202, Halifax

Queen Elizabeth II Health Sciences Centre, Halifax

M5G 2M9

Local Institution - 205, Toronto

Princess Margaret Hospital and University of Toronto, Toronto

00029 HUS

Helsinki UniversityCentral Hospital, Helsinki

Local Institution - 801, Helsinki

00168

Policlinico Agostino Gemelli, Rome

1081 HV

Local Institution - 704, Amsterdam

VU Medical Center, Amsterdam

3015 CN

Erasmus Medical Center, Rotterdam

Local Institution - 703, Rotterdam

08918

Hopsital Germans Trias I Pujol, Badalona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY